A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Public ClinicalTrials.gov record NCT00391729. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Study identification
- NCT ID
- NCT00391729
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Abbott
- Industry
- Enrollment
- 221 participants
Conditions and interventions
Conditions
Interventions
- ABT-089 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2006
- Primary completion
- May 31, 2007
- Completion
- May 31, 2007
- Last update posted
- Oct 17, 2011
2006 – 2007
United States locations
- U.S. sites
- 23
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Mesa | Arizona | 85210 | — |
| Not listed | Lafayette | California | 94549 | — |
| Not listed | Oceanside | California | 92056 | — |
| Not listed | San Diego | California | 92103 | — |
| Not listed | Denver | Colorado | 80212 | — |
| Not listed | Jacksonville | Florida | 32216 | — |
| Not listed | Maitland | Florida | 32751 | — |
| Not listed | Miami | Florida | 33173 | — |
| Not listed | Tampa | Florida | 33606 | — |
| Not listed | Newton | Kansas | 67114 | — |
| Not listed | Farmington Hills | Michigan | 48336 | — |
| Not listed | Omaha | Nebraska | 68198 | — |
| Not listed | Bridgewater | New Jersey | 10312 | — |
| Not listed | New York | New York | 10010 | — |
| Not listed | Staten Island | New York | 10312 | — |
| Not listed | Chapel Hill | North Carolina | 27514 | — |
| Not listed | Lyndhurst | Ohio | 44124 | — |
| Not listed | Portland | Oregon | 97210 | — |
| Not listed | Charleston | South Carolina | 29405 | — |
| Not listed | Memphis | Tennessee | 38119 | — |
| Not listed | Lake Jackson | Texas | 77566 | — |
| Not listed | Herndon | Virginia | 20170 | — |
| Not listed | Middleton | Wisconsin | 53562 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00391729, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 17, 2011 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00391729 live on ClinicalTrials.gov.